A detailed history of Captrust Financial Advisors transactions in Amarin Corp Plcuk stock. As of the latest transaction made, Captrust Financial Advisors holds 20,269 shares of AMRN stock, worth $11,350. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,269
Previous 20,269 -0.0%
Holding current value
$11,350
Previous $18,000 27.78%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.82 - $1.35 $410 - $675
-500 Reduced 2.41%
20,269 $18,000
Q4 2023

Feb 14, 2024

BUY
$0.66 - $0.91 $1,357 - $1,871
2,057 Added 10.99%
20,769 $18,000
Q3 2023

Nov 14, 2023

BUY
$0.85 - $1.43 $5,250 - $8,833
6,177 Added 49.28%
18,712 $17,000
Q1 2023

May 15, 2023

BUY
$1.19 - $2.19 $14,916 - $27,451
12,535 New
12,535 $18,000
Q3 2022

Nov 16, 2022

SELL
$1.09 - $1.67 $16,929 - $25,938
-15,532 Reduced 55.34%
12,535 $14,000
Q2 2022

Aug 23, 2022

SELL
$1.13 - $3.69 $1 - $3
-1 Reduced -0.0%
28,067 $42,000
Q2 2022

Aug 16, 2022

SELL
$1.13 - $3.69 $9,716 - $31,730
-8,599 Reduced 23.45%
28,068 $42,000
Q1 2022

May 16, 2022

BUY
$2.85 - $3.73 $18,952 - $24,804
6,650 Added 22.15%
36,667 $121,000
Q4 2021

Feb 14, 2022

BUY
$3.24 - $5.18 $4,860 - $7,770
1,500 Added 5.26%
30,017 $101,000
Q2 2021

Aug 16, 2021

SELL
$4.26 - $6.5 $3,408 - $5,200
-800 Reduced 2.73%
28,517 $125,000
Q1 2021

May 17, 2021

BUY
$5.03 - $8.8 $45,933 - $80,361
9,132 Added 45.24%
29,317 $182,000
Q4 2020

Feb 16, 2021

SELL
$4.04 - $5.31 $5,959 - $7,832
-1,475 Reduced 6.81%
20,185 $99,000
Q3 2020

Nov 17, 2020

BUY
$3.64 - $7.76 $17,472 - $37,248
4,800 Added 28.47%
21,660 $92,000
Q2 2020

Aug 14, 2020

BUY
$4.78 - $8.26 $80,590 - $139,263
16,860 New
16,860 $119,000

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $226M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.